New sensitive method for the measurement of lysozyme and lactoferrin to explore mucosal innate immunity. Part II: Time-resolved immunofluorometric assay used in HIV patients with oral candidiasis

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 2, 2003, Pages 134-138

  Laibe, Sophy ^a   Bard, Emmanuel ^a   Biichlé, Sabéha ^a   Vielle, Julien ^a   Millon, Laurence ^a   Drobacheff, Christine ^a,b   Seilles, Estelle ^a   Meillet, Dominique ^a,c  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c Laboratoire de Biologie   (France)

Author keywords

Candidiasis; Human immunodeficiency virus (HIV); Innate immunity; Lactoferrin; Lysozyme

Indexed keywords

ALBUMIN; LACTOFERRIN; LYSOZYME;

ADULT; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; EXCRETION; FEMALE; FLUOROMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MUCOSAL IMMUNITY; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; REVIEW; SALIVA ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL PARAMETERS; THRUSH; VALIDATION PROCESS;

CANDIDIASIS, ORAL; FEMALE; FLUOROIMMUNOASSAY; HIV INFECTIONS; HUMANS; LACTOFERRIN; MALE; MUCOUS MEMBRANE; MURAMIDASE; REFERENCE STANDARDS; SALIVA; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0037228842     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.022     Document Type: Review

References (22)

1. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998; 26:259-72; 273-4.
2. Drobacheff C, Millon L, Monod M, Piarroux R, Robinet E, Laurent R, et al. Increased serum and salivary immunoglobulins against Candida albicans in HIV-infected patients with oral candidiasis. Clin Chem Lab Med 2001; 39:519-26.
3. Pruitt KM, Rahemtulla B, Rahemtulla F, Russell MW. Innate humoral factors. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGee JR, editors. Handbook of mucosal immunology, vol 1. London: Academic Press, 1999:65-88.
4. Yeh CK, Dodds MW, Zuo P, Johnson DA. A population-based study of salivary lysozyme concentrations and Candida counts. Arch Oral Biol 1997; 42:25-31.
5. Steinrauf LK, Shiuan D, Yang WJ, Chiang MY. Lysozyme association with nucleic acids. Biochem Biophys Res Commun 1999; 266:366-70.
6. Wu T, Samaranayake LP, Leung WK, Sullivan PA. Inhibition of growth and secreted aspartyl proteinase production in Candida albicans by lysozyme. J Med Microbiol 1999; 48:721-30.
7. Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica 1995; 80:252-67.
8. Okutomi T, Abe S, Tansho S, Wakabayashi H, Kawase K, Yamaguchi H. Augmented inhibition of growth of Candida albicans by neutrophils in the presence of lactoferrin. FEMS Immunol Med Microbiol 1997; 18:105-12.
9. Oseas R, Yang HH, Baehner RL, Boxer LA. Lactoferrin: a promoter of polymorphonuclear leukocyte adhesiveness. Blood 1981; 57:939-45.
10. Bard E, Laibe S, Bettinger D, Riethmuller D, Biichle S, Seilles E, et al. A new sensitive method for the measurement of lysozyme and lactoferrin to explore mucosal innate immunity. Part I: time-resolved immunofluorometric assay in serum and mucosal secretions. Clin Chem Lab Med 2002; 41:127-33.
11. Delacroix DL, Vaerman JP. Influence of molecular size of IgA on its immunoassay by various techniques. III. Immunonephelometry. J Immunol Methods 1982; 51:49-55.
12. Jonard PP, Rambaud JC, Dive C, Vaerman JP, Galian A, Delacroix DL. Secretion of immunoglobulins and plasma proteins from the jejunal mucosa. Transport rate and origin of polymeric immunoglobulin A. J Clin Invest 1984; 74:525-35.
13. Haddad NE, Powderly WG. The changing face of mycoses in patients with HIV/AIDS. AIDS Read 2001; 11:375-8.
14. Servais J, Nkoghe D, Schmit JC, Arendt V, Robert I, Staub T, et al. HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 28:221-5.
15. Muller F, Holberg-Petersen M, Rollag H, Degre M, Brandtzaeg P, Froland SS. Nonspecific oral immunity in individuals with HIV infection. J Acquir Immune Defic Syndr 1992; 5:46-51.
16. Harmsen MC, Swart PJ, de Bethune MP, Pauwels R, de Clercq E, The TH, et al. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human Cytomegalovirus replication in vitro. J Infect Dis 1995; 172:380-8.
17. van der Strate BW, Harmsen MC, The TH, Sprenger HG, de Vries H, Eikelboom MC, et al. Plasma lactoferrin levels are decreased in end-stage AIDS patients. Viral Immunol 1999; 12:197-203.
18. Defer MC, Dugas B, Picard O, Damais C. Impairment of circulating lactoferrin in HIV-1 infection. Cell Mol Biol 1995; 41:417-21.
19. Mandel ID, Barr CE, Turgeon L. Longitudinal study of parotid saliva in HIV-1 infection. J Oral Pathol Med 1992; 21:209-13.
20. Atkinson JC, Yeh C, Oppenheim FG, Bermudez D, Baum BJ, Fox PC. Elevation of salivary antimicrobial proteins following HIV-1 infection. J Acquir Immune Defic Syndr 1990; 3:41-8.
21. Lin AL, Johnson DA, Patterson TF, Wu Y, Lu DL, Shi Q, et al. Salivary anti-candidal activity and saliva composition in an HIV-infected cohort. Oral Microbiol Immunol 2001; 16:270-8.
22. Samaranayake YH, Samaranayake LP, Pow EH, Beena VT, Yeung KW. Antifungal effects of lysozyme and lactoferrin against genetically similar, sequential Candida albicans isolates from a human immunodeficiency virus-infected southern Chinese cohort. J Clin Microbiol 2001; 39:3296-302.